Friday 6 November 2026 Export BRKR’s income statement to Excel — free account

Bruker Corporation

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.

Revenue: +1.57%
EPS: −75.4%
Free cash flow: +278.7%
Total debt: −14.7%

Quarter to September 2026, against a year earlier

61.17 3.11 +5.36%

Follow BRKR

Alert me

Market cap: $8.9B
P/E: 0.0×
Fwd P/E: −412×
Dividend yield: 0.34%
F-score: 4/9
Altman Z: 2.43
Beneish M: −2.56
Dividend safety: 34/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bruker Corporation (BRKR) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2024: revenue by segment, and margins
BSI NANO	1,098	32.63%
BSI CALID	1,094	32.48%
BSI BioSpin	906	26.90%
BEST	269	7.99%
Gross margin		49.00%
Operating margin		7.52%
Pre-tax margin		6.15%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Product	2,766 80.50%	2,759 81.96%	2,458 82.90%	2,110 83.37%	2,017 83.43%	1,638 82.42%	1,745 84.18%	1,577 83.17%	1,480 83.78%	1,345 83.50%
Service and other revenue	670 19.50%	607 18.04%	507 17.10%	421 16.63%	7 0.31%	6 0.30%	6 0.27%	7 0.39%	8 0.46%	11 0.70%
Service	—	—	—	—	393 16.26%	343 17.28%	322 15.56%	312 16.44%	278 15.75%	255 15.81%
Revenue	3,437	3,366	2,965	2,531	2,418	1,988	2,073	1,896	1,766	1,611

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Product	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Service and other revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
License Agreements	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
BSI CALID	1,210 35.22%	1,094 32.48%	960 32.40%	822 32.49%	820 33.90%	654 32.90%	—	—	—	—	—	—	—	—	—
BSI NANO	1,084 31.55%	1,098 32.63%	942 31.77%	787 31.10%	698 28.85%	556 27.98%	—	—	—	—	—	—	—	—	—
BSI BioSpin	879 25.57%	906 26.90%	799 26.94%	697 27.53%	691 28.58%	600 30.19%	—	—	—	—	—	—	—	—	—
BEST	263 7.66%	269 7.99%	264 8.90%	225 8.88%	224 9.26%	190 9.53%	191 10.83%	130 8.08%	134 8.23%	153 8.45%	147 8.01%	136 7.60%	113 6.87%	91 6.94%	60 5.37%
Scientific Instruments	—	—	—	—	—	—	1,071 60.64%	1,493 92.63%	1,499 92.33%	1,675 92.58%	1,710 92.94%	1,666 93.01%	1,554 94.09%	1,225 93.88%	1,063 95.35%
Bruker NANO	—	—	—	—	—	—	513 29.05%	—	—	—	—	—	—	—	—
Eliminations	—	—	—	—	(14) (0.58%)	(12) (0.60%)	(9) (0.52%)	(11) (0.71%)	(9) (0.56%)	(19) (1.03%)	(17) (0.95%)	(11) (0.61%)	(16) (0.96%)	(11) (0.82%)	(8) (0.72%)
Revenue	3,437	3,366	2,965	2,531	2,418	1,988	1,766	1,611	1,624	1,809	1,839	1,791	1,652	1,305	1,115

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Unallocated Expenses	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
BSI CALID	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
BSI BioSpin	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
BSI NANO	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
BEST	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Scientific Instruments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Bruker NANO	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Segment Reconciling Items	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Europe excluding Germany	950 27.65%	873 25.93%	700 23.60%	592 23.39%	658 27.22%	520 26.15%	505 24.38%	500 26.39%	465 26.33%	393 24.42%	480 29.54%	523 28.91%	584 31.73%	531 29.66%	490 29.68%	384 29.44%	341 30.58%
United States	891 25.94%	939 27.88%	778 26.23%	696 27.51%	601 24.86%	456 22.94%	530 25.56%	489 25.82%	435 24.62%	428 26.57%	380 23.43%	388 21.43%	360 19.56%	377 21.06%	309 18.72%	264 20.23%	209 18.77%
Asia Pacific excluding China	553 16.08%	519 15.40%	461 15.55%	408 16.14%	372 15.36%	316 15.88%	651 31.41%	549 28.97%	515 29.15%	458 28.43%	415 25.55%	496 27.39%	529 28.76%	526 29.35%	504 30.49%	343 26.26%	265 23.77%
China	476 13.85%	471 14.00%	528 17.81%	397 15.67%	358 14.79%	314 15.77%	—	—	—	—	—	—	—	—	—	—	—
Germany	297 8.64%	311 9.23%	282 9.50%	247 9.78%	263 10.86%	245 12.32%	214 10.31%	201 10.61%	200 11.34%	190 11.76%	199 12.25%	215 11.89%	189 10.27%	175 9.76%	195 11.82%	182 13.92%	192 17.25%
Other	270 7.85%	255 7.56%	217 7.31%	190 7.52%	167 6.91%	138 6.93%	173 8.35%	156 8.21%	151 8.56%	142 8.82%	150 9.24%	188 10.38%	178 9.68%	182 10.18%	153 9.29%	133 10.15%	107 9.64%
Revenue	3,437	3,366	2,965	2,531	2,418	1,988	2,073	1,896	1,766	1,611	1,624	1,809	1,839	1,791	1,652	1,305	1,115

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Constant-exchange rate revenue growth	Q3 FY2026	2.40%	—	—
Organic revenue growth	Q3 FY2026	0.70%	—	—
Remaining performance obligations	Q3 FY2026	$2.8B	$2.1B	+33.52%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019	Q2 FY2019	Q1 FY2019	Q4 FY2018	Q3 FY2018	Q2 FY2018	Q1 FY2018
Constant-exchange rate revenue growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Organic revenue growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.